A PHASE 3, 8-WEEK, PARALLEL GROUP, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ARQ-154 FOAM 0.3% ADMINISTERED QD IN SUBJECTS WITH SEBORRHEIC DERMATITIS

Registry ID

ARQ-154-304

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ARCUTIS BIOTHERAPEUTICS, INC

Start date

2021-06-10

Completion date

2022-04-06

Last update

2021-05-31

Conditions

• SEBORRHEIC DERMATITIS

View on source registry